Health And Pharma
Health & Pharma. Health and Pharma is a new-generation international news and communication platform. Our goal is to collaborate with health science and pharma professionals to report directly from the news sources and strive to be recognized as a trusted news platform.
About Us - Health And Pharma
Health & Pharma. Health and Pharma is a new-generation international news and communication platform. Our goal is to collaborate with health science and pharma professionals to report directly from the news sources and strive to be recognized as a trusted news platform.
Posts | Health And Medicine
Health & Pharma. Health and Pharma is a new-generation international news and communication platform. Our goal is to collaborate with health science and pharma professionals to report directly from the news sources and strive to be recognized as a trusted news platform.
Posts | Health And Medicine
FDA Approves 225Ac-SSO110 Radiopharmaceutical Trial for Small Cell Lung Cancer. FDA & EMA | 14 January 2025
Olaparib Shows Long-term Survival Benefits in BRCA+ and HER2
Dec 13, 2024 · A Transformative Option in Early-Stage Disease. When first announced in 2022, the OlympiA findings led to regulatory approval of olaparib in the adjuvant (post-surgery) setting for certain patients with HER2-negative, BRCA-positive breast cancer.
ONCOLife | Health And Medicine
Feb 19, 2024 · About ONCOLife. ONCOLife as a cutting-edge oncology magazine designed for oncologists and health professionals. It has flexible format, available both in print and online formats in the US and EU, ONCOLife is dedicated to covering key developments in …
Posts | Health And Medicine
Oct 2, 2024 · A New AI-Driven Drug Discovery Company, Xaira Therapeutics, Launches with $1 Billion. Digital Health | 24 April 2024
Posts | Health And Medicine
Nimbus Reports Early Success in Treating Solid Tumors with NDI-101150, an HPK1 Inhibitor. Clinical Trials | 24 May 2024
Durvalumab Granted FDA Priority Review for Muscle-Invasive …
Dec 7, 2024 · Susan Galbraith, Executive Vice President of Oncology R&D at AstraZeneca, emphasized the significance of this breakthrough. “New options for muscle-invasive bladder cancer are vital because nearly half of patients will see their cancer return or progress despite undergoing curative-intent treatment, including removal of their bladder.
Contact Us - Health And Pharma
For General Inquiries: Email: [email protected] Telephone: +1 315 215 1087